	Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
	How Novo Nordisk misread the US market for its weight loss sensation
	This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
	Novo Nordisk halts Wegovy sales on Hims ' Hers, claiming "deceptive marketing" practices
	Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
	Novo Nordisk Has Ended Its Wegovy Deal With Hims ' Hers: Here's What Investors Need to Know
	Novo exits Hims ' Hers partnership, citing ‘deceptive marketing’ concerns
	Pharmalittle: We’re reading about Novo’s Wegovy launch gaffes, a former Pfizer exec’s subpoena, and more